Dicky L Tahapary1,2, Karin de Ruiter2, Ivonne Martin3,4, Eric A T Brienen2, Lisette van Lieshout2, Christa M Cobbaert5, Pradana Soewondo1, Yenny Djuardi6, Aprilianto E Wiria2,6, Jeanine J Houwing-Duistermaat3,7, Erliyani Sartono2, Johannes W A Smit8,9, Maria Yazdanbakhsh2, Taniawati Supali6. 1. Department of Internal Medicine, Division of Endocrinology, Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta. 2. Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. 3. Medical Statistics and Bioinformatics, Leiden University Medical Center, The Netherlands. 4. Department of Mathematics, Parahyangan Catholic University, Bandung, Indonesia. 5. Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, The Netherlands. 6. Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta. 7. Department of Statistics, University of Leeds, United Kingdom. 8. Department of Internal Medicine, Radboud University Medical Centre, Nijmegen. 9. Department of Internal Medicine, Leiden University Medical Center, The Netherlands.
Abstract
Background: Emerging evidence suggests that helminth infections are associated with lower insulin resistance (IR). Current deworming programs might remove this helminth-associated protective effect. Therefore, we evaluated the anthelmintic treatment effect on changes in IR. Methods: We conducted a double-blind, household-cluster-randomized, placebo-controlled clinical trial on Flores island, Indonesia, an area endemic for soil-transmitted helminths (STHs). All subjects received 4 rounds of albendazole or matching placebo with 3-month intervals, for 3 consecutive days. The primary outcome was the change in homeostatic model assessment of IR in those aged >16 years. An intention-to-treat analysis was performed involving all subjects and ad hoc in the helminth-infected subjects. Results: We examined 797 (in 329 households) and 872 (in 353 households) subjects, who were assigned randomly into the albendazole and placebo arms, respectively. Albendazole was associated with a significant reduction in STH prevalence, total immunoglobulin E (IgE), and eosinophil count. Whereas albendazole had no effect on IR (estimated treatment effect, 0.006 [95% confidence interval, -.010 to .021]; P = .48) at the community level, it was associated with a significant increase in IR (estimated treatment effect, 0.031 [95% confidence interval, .004 to .059]; P = .04) (P value for interaction = .01) among helminth-infected subjects as detected by microscopy. Pathway analysis suggested that this might in part be due to an increased body mass index or a reduced eosinophil count. Conclusions: Anthelmintic treatment reduces STH prevalence, total IgE, and eosinophil count but has no effect on IR at the community level. In helminth-infected subjects, treatment significantly increases IR, highlighting the need for metabolic health monitoring with ongoing deworming programs. Clinical Trials Registration: ISRCTN 75636394.
RCT Entities:
Background: Emerging evidence suggests that helminth infections are associated with lower insulin resistance (IR). Current deworming programs might remove this helminth-associated protective effect. Therefore, we evaluated the anthelmintic treatment effect on changes in IR. Methods: We conducted a double-blind, household-cluster-randomized, placebo-controlled clinical trial on Flores island, Indonesia, an area endemic for soil-transmitted helminths (STHs). All subjects received 4 rounds of albendazole or matching placebo with 3-month intervals, for 3 consecutive days. The primary outcome was the change in homeostatic model assessment of IR in those aged >16 years. An intention-to-treat analysis was performed involving all subjects and ad hoc in the helminth-infected subjects. Results: We examined 797 (in 329 households) and 872 (in 353 households) subjects, who were assigned randomly into the albendazole and placebo arms, respectively. Albendazole was associated with a significant reduction in STH prevalence, total immunoglobulin E (IgE), and eosinophil count. Whereas albendazole had no effect on IR (estimated treatment effect, 0.006 [95% confidence interval, -.010 to .021]; P = .48) at the community level, it was associated with a significant increase in IR (estimated treatment effect, 0.031 [95% confidence interval, .004 to .059]; P = .04) (P value for interaction = .01) among helminth-infected subjects as detected by microscopy. Pathway analysis suggested that this might in part be due to an increased body mass index or a reduced eosinophil count. Conclusions: Anthelmintic treatment reduces STH prevalence, total IgE, and eosinophil count but has no effect on IR at the community level. In helminth-infected subjects, treatment significantly increases IR, highlighting the need for metabolic health monitoring with ongoing deworming programs. Clinical Trials Registration: ISRCTN 75636394.
Authors: John Fleming; Gianna Hernandez; Leslie Hartman; Jane Maksimovic; Sara Nace; Benjamin Lawler; Todd Risa; Thomas Cook; Rashmi Agni; Mark Reichelderfer; Christopher Luzzio; Loren Rolak; Aaron Field; Zsuzsanna Fabry Journal: Mult Scler Date: 2017-10-24 Impact factor: 6.312
Authors: Karin de Ruiter; Dicky L Tahapary; Erliyani Sartono; Thomas B Nutman; Johannes W A Smit; Leo Koenderman; Taniawati Supali; Maria Yazdanbakhsh Journal: J Infect Dis Date: 2019-04-16 Impact factor: 5.226
Authors: Bonnie Douglas; Oyebola Oyesola; Martha M Cooper; Avery Posey; Elia Tait Wojno; Paul R Giacomin; De'Broski R Herbert Journal: Annu Rev Immunol Date: 2021-03-01 Impact factor: 28.527
Authors: D L Tahapary; K de Ruiter; I Martin; E A T Brienen; L van Lieshout; Y Djuardi; C C Djimandjaja; J J Houwing-Duistermaat; P Soewondo; E Sartono; T Supali; J W A Smit; M Yazdanbakhsh Journal: Nutr Diabetes Date: 2017-10-16 Impact factor: 5.097